following the money

Houston-based medical device company snags $12.8M in series B

Saranas closed its series B round this week. Photo courtesy of Saranas

A Houston company that's changing the game when it comes to early bleed detection has raised its next round of funding.

Saranas Inc. announced that it closed a $12.8 million series B investment led by Wisconsin-based Baird Capital, the venture capital and global private equity arm of Baird, a global company with a location in Houston. Austin-based S3 Ventures also supported the round.

The company will use the funds to continue its clinical trials, per a news release.

"We are pleased to announce this round of funding led by Baird Capital," says Saranas President and CEO James Reinstein in the release. "It underscores the importance of real-time monitoring of bleeding complications and our opportunity to accelerate the commercialization of Early Bird. We look forward to expanding our clinical evidence through prospective clinical trials and launching next generation products, including Bird on a Wire, to address a much broader range of endovascular procedures."

Saranas received FDA approval for its Early Bird Bleed Monitoring System in 2019, as well as began its clinical trials. The device is designed to detect and track bleeding complications related to endovascular procedures. These medical procedures treat problems, such as aneurysms, that affect blood vessels. Around 20 percent of patients suffer a bleeding complication during endovascular procedures, like transcatheter aortic valve replacement, endovascular aneurysm repair, and percutaneous hemodynamic support. According to the release, the Early Bird remains the first and only device of its kind.

"As the Saranas team will say, 'Bleeding happens, but complications don't have to,'" says Amy Len Kobe, principal with Baird Capital, in the release. "Baird Capital is proud to partner with Saranas to address bleeding complication challenges and provide solutions that improve outcomes and reduce costs for patients, physicians and providers. We are also pleased to invest in Houston, a growing ecosystem of healthcare innovation and a target market for Baird."

Baird has operated an office locally since 1985, and the venture group has a partnership with the Texas Medical Center since 2018.

S3 Ventures also has an established presence in Houston, and health care technology is one of the three verticals the fund focuses on.

"S3 is enthusiastic about Saranas' game-changing medical device advancements," says Brian R. Smith, managing director of S3 Ventures, in the release. "We invest in companies that are re-imagining the way the world works, lives and heals, and we believe Saranas is a perfect representation of this."

Trending News

Building Houston

 
 

Cemvita has some news regarding its C-level execs. Photo courtesy of Cemvita

An innovative Houston startup that's working with energy companies to decarbonize their operations has made changes to its C-suite.

Tara Karimi, who co-founded Cemvita with her brother Moji, has transition to the company's chief science officer. Liz Dennett has been hired to Karimi's previous role of CTO. The changes enable Karimi to focus on leading Cemvita's scientific research and development efforts as well as participating in driving innovation within the biotech industry as a whole, according to the company's press release.

"I'm excited to take on the role of chief science officer at Cemvita and what it represents for our company's growth," says Karimi in the release. "As chief science officer, I look forward to shaping policy and driving the conversation around the role of biotechnology in the energy transition."

As CTO, Dennett will lead the development of Cemvita's unique biotech products that tap into microbes to decarbonize operations on energy plants. Most recently, Dennett was vice president of data architecture and data engineering at Wood Mackenzie. She previously worked in tech and sustainability-focused roles at Hess Corp., Biota Technology, and Amazon Web Services.

“Working with biological systems presents a unique challenge but also a unique opportunity," says Dennett in the release. "It’s uniquely difficult to go from benchtop to in-situ reactors or oil wells with microbes and to achieve the kind of incredible results that we’re seeing in the lab. You need to build teams with deep specializations in chemistry, biology, energy systems, and geology.”

Dennett, who has her PhD and Master's from the University of Wisconsin-Madison and has served on Cemvita's advisory board for about a year, will report to CEO Moji Karimi directly.

“I know that Tara and Liz are going to make history at Cemvita,” says Moji Karimi in the release. “With 15 years of experience using data-driven approaches to solve pressing energy challenges, Liz brings to bear the kind of creativity and expertise that can quickly and meaningfully advance Cemvita’s impact on the Energy Transition.”

Trending News